News

Press Releases

January 19, 2021
Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease
January 12, 2021
Verve Therapeutics Announces Data Demonstrating Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates
January 6, 2021
Verve Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
November 23, 2020
Verve Therapeutics to Present at the Piper Sandler Annual Virtual Healthcare Conference
See all

Media Contact
Gina Nugent
Ten Bridge Communications
(617) 460-3579
gina@tenbridgecommunications.com

Presentations and Publications

January 12, 2021
Verve Therapeutics Corporate Presentation
39th Annual J.P. Morgan Healthcare Conference
June 27, 2020
Sekar Kathiresan, M.D., Keynote Presentation
International Society for Stem Cell Research Virtual 2020 Meeting
April 8, 2019
Genetics of Common, Complex Coronary Artery Disease
Cell
February 11, 2019
Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing
Nature Biotechnology
See all

In the News

March 4, 2021
CRISPR 2.0: Base Editing in the Groove
Genetic Engineering & Biotechnology News
January 19, 2021
Beam, Verve stockpile cash as investors bank on gene editing progress
BioPharma Dive
January 12, 2021
Why Verve chose base editing over standard CRISPR for its lead CV candidate
BioCentury
January 12, 2021
With durable monkey data, Verve selects its first CRISPR base editing treatment for human trials
STAT News
See all
 

Stay Connected

Find us on LinkedIn and Twitter